NASDAQ: PTGXProtagonist Therapeutics Inc Stock
$56.37+0.05 (+0.09%)
Updated Jun 13, 2025
PTGX Price
$56.37
Fair Value Price
N/A
Market Cap
$3.49B
52 Week Low
$30.67
52 Week High
$60.60
P/E
62.63x
P/B
5.07x
P/S
14.65x
PEG
N/A
Dividend Yield
N/A
Revenue
$207.80M
Earnings
$56.19M
Gross Margin
100%
Operating Margin
27.47%
Profit Margin
27%
Debt to Equity
0.08
Operating Cash Flow
$337M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTGX Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTGX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTGX
Ranked#191 of 464
Ranked#191 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important PTGX news, forecast changes, insider trades & much more!
PTGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTGX was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PTGX is poor value based on its earnings relative to its share price (62.63x), compared to the US market average (31.36x)
P/E vs Market Valuation
PTGX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PTGX due diligence checks available for Premium users.
Valuation
PTGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
62.63x
Industry
-108.97x
Market
31.36x
PTGX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PTGX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PTGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.07x
Industry
4.66x
PTGX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTGX's financial health
Profit margin
Revenue
$28.3M
Net Income
-$11.7M
Profit Margin
-41.2%
PTGX's Earnings (EBIT) of $57.09M... subscribe to Premium to read more.
Interest Coverage Financials
PTGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$742.1M
Liabilities
$53.1M
Debt to equity
0.08
PTGX's short-term assets ($605.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTGX's short-term assets ($605.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$125.4M
Investing
-$94.4M
Financing
$11.4M
PTGX's operating cash flow ($336.94M)... subscribe to Premium to read more.
Debt Coverage Financials
PTGX vs Biotech Stocks
Protagonist Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.